Yes, Korsuva Treats Itching in Kidney Disease
Korsuva (difelikefalin) is FDA-approved for pruritus, or chronic kidney disease-associated pruritus (CKD-aP), in adults undergoing hemodialysis. It targets itching caused by advanced chronic kidney disease (CKD stage 5), where up to 60% of patients experience severe, unrelenting itch that disrupts sleep and quality of life.[1]
How Korsuva Works for CKD-aP
Difelikefalin is a selective kappa opioid receptor agonist given intravenously during dialysis sessions, three times weekly. It activates kappa receptors in the peripheral nervous system and immune cells to reduce itch signaling without crossing the blood-brain barrier significantly, minimizing central side effects like sedation common in older opioids.[1][2]
Who Qualifies and When It's Prescribed
Prescribed for CKD patients on maintenance hemodialysis with moderate-to-severe pruritus lasting over six weeks, unresponsive to other treatments. It's not approved for earlier CKD stages, peritoneal dialysis, or non-dialysis patients.[1]
Effectiveness from Clinical Trials
In phase 3 trials (KALM-1 and KALM-2), 40-50% of Korsuva patients achieved a ≥3-point reduction in Worst Itching Intensity (WI-NRS) score over 24 weeks, compared to 25-30% on placebo. Itch severity dropped faster, with benefits seen by week 4. Quality-of-life measures also improved.[2][3]
Common Side Effects and Risks
Most frequent: diarrhea (20-30%), dizziness (10-15%), nausea (10-15%), and hyperkalemia (elevated potassium, 10%). Rare risks include hypersensitivity reactions or respiratory depression. Avoid in hepatic impairment; monitor potassium levels.[1]
How It Compares to Other Itch Treatments
| Treatment | Type | Administration | Key Differences from Korsuva |
|-----------|------|----------------|-----------------------------|
| Gabapentin/pregabalin | Anticonvulsant | Oral, post-dialysis | Off-label; sedating, less targeted to kappa pathway |
| Nalfurafine (Japan only) | Kappa agonist | IV | Similar mechanism but CNS effects; not U.S.-approved |
| Capsaicin cream | Topical | Applied to skin | Local relief only; burning sensation common |
| UV phototherapy | Non-drug | Clinic sessions | Effective for some; time-intensive, skin cancer risk |
Korsuva outperforms placebo more consistently in head-to-head data but lacks direct comparisons.[2]
Availability, Dosing, and Cost
Administered as 0.5 mcg/kg IV at each dialysis session end. Developed by Cara Therapeutics and marketed by Vifor Fresenius Medical Care Renal Pharma. List price around $1,200 per dose (U.S., 2023), often covered by dialysis bundles or Medicare Part B.[4]
Ongoing Research and Limitations
Phase 3 trials explore oral difelikefalin for non-dialysis CKD pruritus. Patent protection lasts until at least 2032 in the U.S. (check DrugPatentWatch.com for expirations).[5] Not a cure; itch may return if stopped.
Sources
[1] Korsuva Prescribing Information (FDA)
[2] New England Journal of Medicine (KALM Trials)
[3] Fishbane et al., NEJM 2021 (KALM-2)
[4] GoodRx Pricing Data
[5] DrugPatentWatch.com - Difelikefalin Patents